Compare Axogen Inc (AXGN) vs Cardinal Health Inc (CAH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Cardinal Health Inc — how do they compare? Axogen Inc trades at $47.92 (market cap $2.67B), while Cardinal Health Inc trades at $231.36 (market cap $54.46B). The key difference: Cardinal Health Inc is far larger — about 20.4× Axogen Inc's market cap, and Cardinal Health Inc pays a 0.88% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | CAH | |
|---|---|---|
Market Cap | $2.67B | $54.46B |
Sector | Technology | Health |
52-Week High | $49.67 | $240.26 |
52-Week Low | $14.79 | $146.04 |
Enterprise Value | $2.58B | $58.49B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 2.45% today, showing strong momentum near resistance at $50. The stock maintains a bullish technical outlook with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, revenue growth remains robust with Q2 2026 sales up 23.1% to $69.7 million and full-year guidance raised to at least $279 million, but profitability challenges persist with negative net margins and recent earnings misses.
Analyst consensus remains strongly bullish with 84% buy ratings and a $54.33 price target, representing 9.4% upside potential. Key investment opportunities include expanding nerve care platform adoption and reimbursement improvements, while risks include ongoing profitability challenges, competitive pressures, and reliance on elective procedure recovery.
Cardinal Health (CAH) trades at $231.24, down 3.75% on the day, following a strong earnings beat in Q2 2026 with EPS of $2.91 versus $2.42 expected. The stock is in a bullish technical trend with moving averages supporting further upside, while fundamentals show robust revenue growth and improved profitability, with a net income margin of 0.67% for 2025. Recent news highlights record highs post-earnings and optimistic fiscal 2027 guidance.
The outlook for CAH is positive, driven by consistent earnings beats, strong analyst buy ratings (54.55%), and a consensus price target of $270.11 implying significant upside. Key risks include high leverage with a debt-to-asset ratio of 16.09 and reliance on pharmaceutical and specialty business segments for growth amidst competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →
